skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Roche's blockbuster cancer drug Avastin (bevacizumab) generated nearly $7bn in revenues in 2018, but Avastin's solid status on Roche's top line will be tested with the launch of the first biosimilar in the US. Allergan PLC and Amgen Inc. launched the first US biosimilar for Avastin and Roche's Herceptin (trastuzumab) on 18 July, marking the first oncology biosimilar launches in the US. 

It's unclear how the commercial dynamics will play out, but Scrip looked at the commercial and development history of Avastin since its first US FDA approval in 2004 for metastatic colon cancer. Avastin was a blockbuster in its first full year on the market. It rose to become Roche's top-selling drug in 2009 before losing that status in 2012 after a breast cancer indication was withdrawn. 








電話:+81 (0)3 6273 4260